Results for Cell-based Assays ( 1230 )
- From: £964.00
The Fc (IgG1): FcRn Inhibitor Screening Chemiluminescent Assay Kit is designed for the screening and profiling of neutralizing antibodies or inhibitors of the interaction between human Fc (IgG1) and human FcRn (Neonatal Fc receptor for IgG). This kit comes in a convenient 96-well or 384-well format, with purified Biotinylated-FcRn complex (Fc receptor amino acids 24-297 and B2M amino acids 21-119) and Fc (IgG1) (amino acids 100-330) proteins, Streptavidin-HRP, and assay buffers for 100 or 400 reactions. A 96-well plate is coated with Fc (IgG1) protein. After blocking, the plate is pre-incubated with an inhibitor or neutralizing antibody. Upon subsequent incubation with Biotin-FcRn, the plate is treated with Streptavidin-HRP followed by addition of the ELISA ECL substrate to produce chemiluminescence that can be measured using a chemiluminescence reader. The chemiluminescence signal is proportional to the binding of FcRn to Fc (IgG1).
- From: £1,644.00
The Fc (IgG1): FcRn Inhibitor Screening Chemiluminescent Assay Kit is designed for the screening and profiling of neutralizing antibodies or inhibitors of the interaction between human Fc (IgG1) and human FcRn (Neonatal Fc receptor for IgG). This kit comes in a convenient 96-well or 384-well format, with purified Biotinylated-FcRn complex (Fc receptor amino acids 24-297 and B2M amino acids 21-119) and Fc (IgG1) (amino acids 100-330) proteins, Streptavidin-HRP, and assay buffers for 100 or 400 reactions. A 96-well plate is coated with Fc (IgG1) protein. After blocking, the plate is pre-incubated with an inhibitor or neutralizing antibody. Upon subsequent incubation with Biotin-FcRn, the plate is treated with Streptavidin-HRP followed by addition of the ELISA ECL substrate to produce chemiluminescence that can be measured using a chemiluminescence reader. The chemiluminescence signal is proportional to the binding of FcRn to Fc (IgG1).
- From: £1,644.00
Please note this product may be subject to fees, we invite you to contact your local office.Nectin-4 Knockout MCF7 Cell Line is an MCF7 breast cancer cell line in which human Nectin-4 has been genetically removed using CRISPR/Cas9 genome editing with a lentivirus encoding CRISPR/Cas9 gene and sgRNA (single guide RNA) targeting human Nectin-4. This cell line has been validated by genomic sequencing and flow cytometry.
- From: £4,702.00
Please note this product may be subject to fees, we invite you to contact your local office.TROP2 Knockout MCF7 Cell Line is an MCF7 breast cancer cell line in which human TROP2 (Trophoblast cell-surface antigen 2 or TACSTD2) has been genetically removed using CRISPR/Cas9 genome editing with a lentivirus encoding CRISPR/Cas9 gene and sgRNA (single guide RNA) targeting human TROP2. This cell line has been validated by genomic sequencing and flow cytometry.
- From: £2,408.00
Please note this product may be subject to fees, we invite you to contact your local office.EGFR Knockout A549 Cell Line is an A549 lung cancer cell line in which human EGFR (epidermal growth factor receptor) has been genetically removed using CRISPR/Cas9 genome editing with a lentivirus encoding CRISPR/Cas9 gene and sgRNA (single guide RNA) targeting human EGFR. This cell line has been validated by genomic sequencing and flow cytometry.
- From: £607.00
Please note this product may be subject to fees, we invite you to contact your local office.Firefly Luciferase BCMA Knockout RPMI-8226 Cell Line is a RPMI-8226 cell Line constitutively expressing firefly (Photinus pyralis) luciferase under the control of a CMV promoter, and in which BCMA (B-Cell Maturation Antigen, or CD269) has been genetically removed using CRISPR/Cas9 genome editing. This cell line was generated by using Firefly Luciferase Lentivirus (BPS Bioscience #79692). This cell line has been validated by genome sequencing, flow cytometry and luciferase activity measurement.
- From: £850.00
Please note this product may be subject to fees, we invite you to contact your local office.PARG Knockout MCF7 Cell Line is an MCF7 breast cancer cell line in which human PARG (Poly ADP-ribose glycohydrolase) has been genetically removed using CRISPR/Cas9 genome editing. This cell line has been validated by genomic sequencing and Western Blot.